Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
June 14, 2024 13:41 ET
|
Scilex Holding Company
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for...
Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
June 13, 2024 09:00 ET
|
Scilex Holding Company
Up to 60% of patients with migraine do not sufficiently respond to triptans.Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
June 11, 2024 19:20 ET
|
Scilex Holding Company
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®
June 11, 2024 09:00 ET
|
Scilex Holding Company
Scilex launched its third commercial product, GLOPERBA® on June 10, 2024.Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent...
Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
June 10, 2024 11:49 ET
|
Scilex Holding Company
Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of stocking by Wednesday June 12, 2024.Today,...
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024
June 06, 2024 14:56 ET
|
Scilex Holding Company
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
May 30, 2024 13:19 ET
|
Scilex Holding Company
PALO ALTO, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index
May 24, 2024 13:40 ET
|
Scilex Holding Company
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company
May 24, 2024 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
May 14, 2024 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...